Key result
Congestive Heart Failure launches new translational research section to highlight cutting-edge therapeutics.
Why the study?
There is a need to highlight and disseminate cutting-edge translational research in heart failure that rapidly impacts clinical practice.
Answers are grounded in this paper and cite their sources.
With the introduction of this new section, “Spotlight on Heart Failure Translational Research,” Congestive Heart Failure recognizes the importance of the cutting‐edge research that frequently translates to clinical practice in a rapid timeframe. It is the intent of the Co‐Editors in Chief to provide the readership with a window on the future of heart failure therapeutics through the introduction of this section. Dr. George W. Booz, Section Editor for this pivotal area, cordially invites the submission of translational research in all aspects of heart failure for review and potential publication within this section.—John E. Strobeck, MD, PhD and Marc A.
No takes yet. Share an insight, caveat, or question.
George W. Booz (2007) conducted an editorial in Heart failure. The journal Congestive Heart Failure introduced a new section titled Spotlight on Heart Failure Translational Research to highlight cutting-edge therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: